Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glycopyrronium bromide is a synthetic quaternary ammonium compound that acts as a competitive muscarinic acetylcholine receptor antagonist. In the context of primary axillary hyperhidrosis, it is formulated as a 1% cream (Axhidrox) for topical application. By blocking the muscarinic receptors on eccrine sweat glands, it inhibits the stimulation of sweat production by acetylcholine. Developed by Dr. August Wolff GmbH & Co. KG, this topical formulation provides a localized treatment option with reduced systemic anticholinergic side effects compared to oral administration. It is specifically indicated for the treatment of severe primary axillary hyperhidrosis in adults and adolescents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glycopyrronium bromide.